The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | How will bispecifics impact the treatment of NHL?
Catherine Diefenbach, MD, NYU Langone, New York, NY, discusses the potential of bispecific antibodies for non-Hodgkin lymphomas (NHL), highlighting how they will likely be integrated widely across all lines of therapy. She also notes that optimizing the sequencing of bispecific antibodies and CAR-T is a hurdle that must be overcome to bring maximum benefit to patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS: Consultancy, Research Funding; Celgene: Consultancy; FATE Therapeutics: Research Funding; Genentech/Roche: Consultancy, Research Funding; Genmab: Consultancy; Gilead: Current equity holder in publicly-traded company; IMAB: Consultancy; Incyte: Research Funding; Kite: Consultancy; MEI Pharma: Research Funding; Merck: Consultancy, Research Funding; MorphoSys: Consultancy, Research Funding; Seattle Genetics: Research Funding.
